Notably, studies utilizing outlier analysis have identified TM4SF4 and LRRK2 as key oncogenic drivers, demonstrating that transcriptomic profiling can aid in discovering novel targets for personalized cancer therapy [217]. This evidence concerns the gene TM4SF4 and cancer.